As coronary CT angiography (CCTA) continues its rapid expansion, scanner vendors are now offering more economical solutions to ensure access to imaging technology beyond premium systems most often only found at flagship hospitals and academic centers. To conquer CCTA’s technical challenges, new technologies and AI are being incorporated into a new scanner to simplify acquisition and consistently improve image quality. 

“Focusing on programmatic resources in the first follow-up period may provide a significant return on investment," experts write in JAMA Network Open. 

In a prospective study involving 54 adults, ultralow-dose CT, denoised with deep learning, “substantially” cut radiation exposure while accurately detecting pneumonia. 

CT for CRC screening is at an “inflection point” following the Centers for Medicare & Medicaid Services’ recent decision to cover the exam, experts say. 

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.

Not all AI or regression models are the same, nor do they all incorporate the same data when assessing patient risk.

CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.